-0.15%
0.76%
-14.42%
-12.60%
39.03%
17.26%
26.25%
AI Spotlight on ABUS
Company Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States.Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication.The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19.
It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc.Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection.The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015.
Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Market Data
| Last Price | 3.29 |
| Change Percentage | -0.15% |
| Open | 3.28 |
| Previous Close | 3.3 |
| Market Cap ( Millions) | 624 |
| Volume | 45342 |
| Year High | 4.72 |
| Year Low | 2.27 |
| M A 50 | 3.4 |
| M A 200 | 3.52 |
Financial Ratios
| FCF Yield | -11.31% |
| Dividend Yield | 0.00% |
| ROE | -68.18% |
| Debt / Equity | 1.35% |
| Net Debt / EBIDTA | 40.46% |
| Price To Book | 5.83 |
| Price Earnings Ratio | -8.12 |
| Price To FCF | -8.84 |
| Price To sales | 92.61 |
| EV / EBITDA | -7.9 |
News
- Jan -30 - Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.
- Jan -13 - Arbutus Provides 2025 Corporate and Financial Update
- Jan -07 - Arbutus: Positive Imdusiran Data Leads To Phase 2B Development
- Nov -26 - Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
- Nov -15 - Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
- Nov -15 - Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
- Nov -14 - Arbutus to Present at Jefferies London Healthcare Conference
- Nov -06 - Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript
- Nov -06 - Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates
- Oct -23 - Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
- Oct -15 - Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
- Sep -25 - Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year?
- Sep -03 - Arbutus to Participate in Two Upcoming Investor Conferences
- Aug -22 - Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?
- Aug -06 - Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
- Aug -01 - Arbutus Layoffs 2024: What to Know About the Latest ABUS Job Cuts
- Aug -01 - Arbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call Transcript
- Aug -01 - Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates
- Aug -01 - Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Jul -18 - Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Novel Therapeutics
Expected Growth : 9.27 %
What the company do ?
Arbutus Biopharma's Novel Therapeutics are RNAi-based treatments for Hepatitis B, utilizing proprietary LNP technology to deliver gene silencing therapies.
Why we expect these perspectives ?
Arbutus Biopharma's Novel Therapeutics segment growth is driven by increasing adoption of RNAi-based treatments, strong pipeline of HBV and HIV therapies, and strategic partnerships. The company's proprietary LNP delivery technology and AB-729 candidate's promising Phase 1a results also contribute to growth. Additionally, the growing demand for innovative therapies and increasing investment in gene editing technologies support the segment's 9.27% growth.
Arbutus Biopharma Corporation Products
| Product Range | What is it ? |
|---|---|
| AB-729 | A RNA interference (RNAi) therapeutic candidate for the treatment of chronic hepatitis B virus (HBV) infection |
| AB-836 | A next-generation RNAi therapeutic candidate for the treatment of chronic HBV infection |
| AB-101 | A proprietary GalNAc-conjugated RNAi therapeutic candidate for the treatment of chronic HBV infection |
| LNP (Lipid Nanoparticle) Delivery Technology | A proprietary delivery technology for RNAi therapeutics, enabling targeted delivery to the liver |
Arbutus Biopharma Corporation's Porter Forces
Threat Of Substitutes
Arbutus Biopharma Corporation has a moderate threat of substitutes due to the availability of alternative treatments for hepatitis B, such as nucleoside analogues and interferons. However, the company's proprietary RNAi technology provides a unique mechanism of action that differentiates its products from existing treatments.
Bargaining Power Of Customers
Arbutus Biopharma Corporation's customers, primarily pharmaceutical companies and research institutions, have limited bargaining power due to the company's specialized RNAi technology and the high barriers to entry in the biotech industry.
Bargaining Power Of Suppliers
Arbutus Biopharma Corporation's suppliers, including contract manufacturers and raw material providers, have moderate bargaining power due to the company's dependence on a limited number of suppliers for critical components and materials.
Threat Of New Entrants
Arbutus Biopharma Corporation faces a high threat of new entrants due to the growing interest in RNAi technology and the increasing availability of funding for biotech startups. New entrants could potentially disrupt the market and compete with the company's products.
Intensity Of Rivalry
Arbutus Biopharma Corporation operates in a highly competitive industry with several established players, including Gilead Sciences and GlaxoSmithKline. The company faces intense rivalry in the development of hepatitis B treatments, which could impact its market share and revenue.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 6.51% |
| Debt Cost | 5.26% |
| Equity Weight | 93.49% |
| Equity Cost | 13.81% |
| WACC | 13.26% |
| Leverage | 6.96% |
Arbutus Biopharma Corporation : Quality Control
Arbutus Biopharma Corporation passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| OCUL | Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company … |
| LPCN | Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral … |
| EYPT | EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, … |
| PSTX | Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) … |
| BCRX | BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Ocular Therapeutix
A-Score
1-Year Total Return ->
🥈
Arbutus Biopharma
A-Score
1-Year Total Return ->
🥉
Lipocine
A-Score
1-Year Total Return ->
4
BioCryst Pharmaceuticals
A-Score
1-Year Total Return ->
5
Poseida Therapeutics
A-Score
1-Year Total Return ->
6
